Skip to content

Comparation of equal doses of bupivacaine, levobupivacaine, & ropivacaine in spinal anaesthesia for caesarean section

Comparative evaluation of equipotent doses of hyperbaric bupivacaine, levobupivacaine, & ropivacaine in sub arachnoid block for caesarean section - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/072333
Enrollment
105
Registered
2024-08-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O00-O9A- Pregnancy, childbirth and the puerperium

Interventions

Intervention1: Subarachnoid block in Caesarean section: Injection Levobupivacaine 0.5% 2ml given intrathecally and effect noted with in 24 hours Intervention2: Subarachnoid block in Caesarean section:

Sponsors

Sri Lal Bahadur Shastri Government Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Singleton pregnancy 2. Gestational age more than 34 weeks, 3. Age between 18-40years

Exclusion criteria

Exclusion criteria: 1. Patient denial/unwillingness 2. Patient with known sensitivity to local anaesthetic drugs. 3. Local infection at the site where needle for block is to be inserted.

Design outcomes

Primary

MeasureTime frame
To assess the onset and duration of motor and sensory block and maximum level of sensory block achieved with intrathecal administration of hyperbaric Bupivacaine (0.5%), hyperbaric Levobupivacaine (0.5%) and hyperbaric Ropivacaine (0.75%) for spinal anaesthesia in caesarean section.Timepoint: From baseline to maximum of 24 hours from start of surgery

Secondary

MeasureTime frame
1) To evaluate the hemodynamic changes associated with these drugs. 2) To check for any side effects.Timepoint: 45 minutes

Countries

India

Contacts

Public ContactDr Vikas Dogra

Sri Lal Bahadur Shastri Government Medical College and Hospital

shalini.medico@gmail.com9418011121

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026